Foot-and-mouth disease virus localisation on follicular dendritic cells and sustained induction of neutralising antibodies is dependent on binding to complement receptors (CR2/CR1).
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
07
09
2021
accepted:
12
04
2022
revised:
17
05
2022
pubmed:
6
5
2022
medline:
20
5
2022
entrez:
5
5
2022
Statut:
epublish
Résumé
Previous studies have shown after the resolution of acute infection and viraemia, foot-and-mouth disease virus (FMDV) capsid proteins and/or genome are localised in the light zone of germinal centres of lymphoid tissue in cattle and African buffalo. The pattern of staining for FMDV proteins was consistent with the virus binding to follicular dendritic cells (FDCs). We have now demonstrated a similar pattern of FMDV protein staining in mouse spleens after acute infection and showed FMDV proteins are colocalised with FDCs. Blocking antigen binding to complement receptor type 2 and 1 (CR2/CR1) prior to infection with FMDV significantly reduced the detection of viral proteins on FDCs and FMDV genomic RNA in spleen samples. Blocking the receptors prior to infection also significantly reduced neutralising antibody titres, through significant reduction in their avidity to the FMDV capsid. Therefore, the binding of FMDV to FDCs and sustained induction of neutralising antibody responses are dependent on FMDV binding to CR2/CR1 in mice.
Identifiants
pubmed: 35512014
doi: 10.1371/journal.ppat.1009942
pii: PPATHOGENS-D-21-01837
pmc: PMC9113581
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Capsid Proteins
0
Receptors, Complement
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009942Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007032
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007037
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007039
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/D/20002174
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Infect Dis. 2022 May 4;225(9):1533-1544
pubmed: 33534885
EMBO J. 1997 Jun 2;16(11):2996-3006
pubmed: 9214617
Nat Immunol. 2020 Jun;21(6):649-659
pubmed: 32424359
J Immunol. 1998 Nov 15;161(10):5373-81
pubmed: 9820511
J Virol. 2016 Apr 29;90(10):5132-5140
pubmed: 26962214
PLoS One. 2008;3(10):e3434
pubmed: 18941503
Front Immunol. 2021 Apr 12;12:655753
pubmed: 33912182
Annu Rev Immunol. 1998;16:545-68
pubmed: 9597141
Vaccine. 2002 Jun 7;20(19-20):2508-15
pubmed: 12057606
J Exp Med. 2006 Oct 30;203(11):2419-24
pubmed: 17030950
Trends Immunol. 2014 Mar;35(3):105-13
pubmed: 24315719
J Gen Virol. 2014 Nov;95(Pt 11):2329-2345
pubmed: 25000962
Vaccine. 2003 Sep 8;21(25-26):3751-6
pubmed: 12922108
J Immunol. 2000 May 1;164(9):4522-32
pubmed: 10779753
Science. 2021 Oct;374(6563):104-109
pubmed: 34591637
Nat Immunol. 2000 Aug;1(2):127-31
pubmed: 11248804
Immunol Rev. 2019 Mar;288(1):49-63
pubmed: 30874353
Oligonucleotides. 2006 Winter;16(4):395-403
pubmed: 17155914
Vaccine. 2005 Jan 19;23(9):1106-13
pubmed: 15629353
J Neurosci Methods. 2003 Feb 15;123(1):31-45
pubmed: 12581847
Immunology. 2000 May;100(1):4-12
pubmed: 10809953
Mol Immunol. 2015 Feb;63(2):479-88
pubmed: 25457881
J Exp Med. 1999 Oct 18;190(8):1165-74
pubmed: 10523614
Vaccine. 2008 Dec 30;26 Suppl 8:I28-33
pubmed: 19388161
Immunity. 1996 Mar;4(3):251-62
pubmed: 8624815
Immunol Rev. 2003 Aug;194:8-18
pubmed: 12846803
J Virol. 2016 Jun 24;90(14):6344-64
pubmed: 27147736
PLoS Pathog. 2013 Mar;9(3):e1003255
pubmed: 23544011
J Immunol. 2008 Sep 1;181(5):2953-9
pubmed: 18713965
J Exp Med. 2002 Nov 4;196(9):1189-99
pubmed: 12417629
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3357-61
pubmed: 8622941
mSphere. 2018 Sep 12;3(5):
pubmed: 30209130
Science. 1996 Jan 19;271(5247):348-50
pubmed: 8553069
Cornell Vet. 1964 Oct;54:501-10
pubmed: 14234053
mSphere. 2018 Dec 12;3(6):
pubmed: 30541776
J Immunol. 2007 Nov 1;179(9):5877-85
pubmed: 17947661
Immunity. 2020 Dec 15;53(6):1136-1150
pubmed: 33326765
Nat Med. 2001 Apr;7(4):485-7
pubmed: 11283677
J Immunol. 2018 Aug 15;201(4):1315-1326
pubmed: 30006374
J Gen Virol. 2000 Jul;81(Pt 7):1669-73
pubmed: 10859371
J Immunol. 1998 Jun 1;160(11):5273-9
pubmed: 9605124
Comp Immunol Microbiol Infect Dis. 1985;8(3-4):259-65
pubmed: 3004803
J Comp Pathol. 2003 Jul;129(1):1-36
pubmed: 12859905
Eur J Immunol. 1996 Feb;26(2):444-8
pubmed: 8617316
J Comp Pathol. 1979 Oct;89(4):541-9
pubmed: 232107
PLoS Pathog. 2011 Dec;7(12):e1002402
pubmed: 22144895
Vet Rec. 1965 Aug 14;77(33):968-9
pubmed: 5890082
J Immunol Methods. 2005 Jul;302(1-2):156-67
pubmed: 15992812
Immunity. 2006 Jan;24(1):65-77
pubmed: 16413924
J Comp Pathol. 1972 Jan;82(1):19-28
pubmed: 4336115
Virology. 1995 Oct 1;212(2):614-21
pubmed: 7571431
J Immunol. 2007 Jun 1;178(11):6968-74
pubmed: 17513746
Emerg Infect Dis. 2005 Dec;11(12):1887-93
pubmed: 16485475
Pathol Int. 1996 Nov;46(11):807-33
pubmed: 8970191
J Gen Virol. 2013 Jan;94(Pt 1):97-107
pubmed: 23034593
Nat Med. 2001 Apr;7(4):488-92
pubmed: 11283678
J Vet Diagn Invest. 2006 Jan;18(1):93-7
pubmed: 16566264
PLoS Pathog. 2015 Dec 01;11(12):e1005285
pubmed: 26623655
Microbes Infect. 2002 Aug;4(10):1099-110
pubmed: 12191660
Nat Rev Immunol. 2014 Jul;14(7):495-504
pubmed: 24948364
Immunity. 2013 Jun 27;38(6):1164-75
pubmed: 23770227
J Virol. 2009 Apr;83(8):3626-36
pubmed: 19176618
J Gen Virol. 2016 Sep;97(9):2201-2209
pubmed: 27260141
J Immunol. 2000 Jun 15;164(12):6268-75
pubmed: 10843680
Vaccine. 2011 Mar 24;29(15):2682-90
pubmed: 21316500
J Exp Med. 1996 May 1;183(5):2259-69
pubmed: 8642335